Cornell University researchers used a new technology to design a vaccine that they say provides full protection against both ...

The COVID-19 vaccine has prompted more than 10 times as many reports of adverse symptoms than the measles vaccine.

Cornell researchers have developed a new vaccine platform that could provide more robust, longer-lasting protection from both ...

Department of Health and Human Services Secretary Robert F. Kennedy Jr. paused a $240 million contract to create a new coronavirus vaccine.

Recent Studies Support Diversified Vaccine Strategies, Aligning with GeoVax's MVA-Based GEO-CM04S1 for Enhanced Protection, ...

When COVID-19 vaccines rolled out, public health officials largely followed a simple logic: protect the most vulnerable first ...

Results of IMNN-101 Proof-of-Concept study demonstrate persistent immunogenicity in trial participants and further validate PlaCCine® ...

Yale researchers have found clues as to why certain people experience adverse health effects after the COVID-19 vaccine, ...

Federal funding for a Bay Area biotech company's potential half-billion-dollar oral Covid-19 vaccine project has been paused ...

The proof-of-concept study is one of the first to combine B and T cell analysis and potentially paves the way for tests that ...

As the industry moves towards a more integrated and diversified vaccine ecosystem, GeoVax’s MVA-based vaccines should provide a scalable, durable, and globally accessible solution that enhances the ...

Cornell University researchers have developed a new vaccine platform that could provide more robust, longer-lasting protection from both COVID-19 and influenza, and broader immunity to different flu ...